Pharmaceutical Business
At Sato Pharmaceutical, we are striving to improve patients’ quality of life
by expanding our product lineup, especially in the area of dermatology. We are also
focusing on the development of dosage forms to meet a wide range of needs.
Mainstay Products
Sato is a market leader in the treatment of onychomycosis,
with both topical and oral products that drive our pharmaceutical business.
Onychomycosis TreatmentLUCONAC Solution
Oral Antifungal AgentNAILIN Capsules
In 2016, Sato launched LUCONAC Solution 5%, a topical treatment for onychomycosis, followed by NAILIN Capsules 100mg, an oral formulation in 2018. We are the only pharmaceutical company in Japan that provides both topical and oral therapy for onychomycosis, putting us in a leading position in the domestic nail fungus treatment market. Furthermore, we obtained approval in Singapore for LUCONAC, External Solution for Nails 5% w/w, representing the first step in our global expansion.
Topical AnestheticEMLA
In 2012, Sato launched EMLA Cream, Japan’s first effective topical anesthetic pain-reduction therapy for dermatological laser radiation treatment. In 2015, application was expanded for relief of pain during injections and puncture of intravenous indwelling needle. In 2017, the EMLA Patch, a one-touch procedure, was launched as an additional dosage form. In 2018, EMLA took the top share in the domestic external anesthetic market (based on NHI price) in Japan, and has maintained this position every year since.
Urea PreparationPASTARON
Acne RemedyDALACIN
Diagnostic AgentPATCH TEST PANEL
Sato Pharmaceutical is also developing other unique products, primarily in the field of dermatology. PASTARON, a urea preparation, has been expanded to include a variety of products, and has been in use in the medical field for many years. We also address a wide range of needs in the medical field with products including DALACIN, an acne remedy, and PATCH TEST PANEL (S), a diagnostic agent for allergic dermatitis, contributing to improving patients’ quality of life.
Marketing
Activities Designed to Provide Detailed Information
Sato Pharmaceutical actively promotes awareness of and
provides accurate information on onychomycosis treatment.
We are taking a multifaceted approach, offering web seminars for
HCPs (healthcare professionals) and utilizing TV commercials and
our website for patients.
-
Providing Information and Promoting Public Awareness through Multiple Channels
As a leading company in the treatment of onychomycosis, Sato Pharmaceutical takes a multifaceted approach to delivering information tailored to the needs of healthcare professionals and patients.
Lecture commemorating the sixth anniversary of the launch of
NAILIN Capsules 100mg -
Creating Sato Pharmaceutical’s Unique Web Seminars
For HCPs, we provide the latest treatment insights and practical clinical information on an ongoing basis through specialized lectures and our proprietary web seminar platform, SDO (Sato Derma Online). As of April 2025, approximately 5,800 physicians are registered with SDO, with each seminar attracting 200 to 300 HCPs.
Original seminar distribution platform -
Patient Education Activities Focused on Disease Awareness, Delivered through Multiple Channels
Sato Pharmaceutical actively carries out awareness initiatives to encourage a proper understanding of and early medical consultation for onychomycosis—a condition often overlooked but can significantly impact quality of life. Sato utilizes a wide range of channels, including disease awareness websites, TV commercials, digital ads and social media, to provoke people to question whether they might have this medical condition.
Nail fungus awareness TV commercial
